Lupin launches generic Pristiq tablets in US

02 Mar 2017 Evaluate

Lupin has launched generic Pristiq (Desvenlafaxine Succinate) Extended-Release Tablets, 50 mg and 100 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier. Lupin’s Desvenlafaxine Succinate Extended-Release Tablets, 50 mg and 100 mg, is the AB rated generic equivalent of Wyeth Pharmaceuticals’ Pristiq Tablets. It is indicated for the treatment of major depressive disorder (MDD). Pristiq tablets had annual US sales of around $859.9 million as per IMS MAT December 2016.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin Share Price

2151.05 19.25 (0.90%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×